Synthesis and Cytotoxic Activity of (4-Substituted-benzylidene)-(3-Phenyl-1,2,4-Oxadiazol-5-YL)Methylamines
- Autores: Kucukoglu K.1, Tugrak M.1, Demirtas A.1, Sakagami H.2, Gul H.1
-
Afiliações:
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ataturk University
- Division of Pharmacology, School of Dentistry, Meikai University
- Edição: Volume 50, Nº 4 (2016)
- Páginas: 234-238
- Seção: Article
- URL: https://journals.rcsi.science/0091-150X/article/view/244350
- DOI: https://doi.org/10.1007/s11094-016-1429-7
- ID: 244350
Citar
Resumo
This work was aimed at the synthesis and investigation of the cytotoxic activity of a series of Schiff bases having (4-substituted-benzylidene)-(3-phenyl-1,2,4-oxadiazol-5-yl)methylamine structure with different electronic natures of substituents in the phenyl ring. Thus, the study was intended to observe the effect of substituents with different electronic properties on the cytotoxic activity. The synthesized series of compounds (OP) were obtained by six-step synthesis with yields ranging from 12.23 to 25.77%. The chemical structures of these compounds were elucidated by H NMR. The cytotoxicity of compounds against human oral squamous cell carcinoma cell lines [Ca9-22 (gum), HSC-2 (mouth), HSC-3 (fluent), HSC-4 (language)] and human oral normal cells [HGF (gum fibroblasts), HPC (pulp cells), and HPLF (periodontal ligament fibroblasts)] was tested by MTT assay. Among the group of six OP compounds, bromo derivative OP2, non-substituted derivative OP1, and chloro derivative OP3 showed higher cytotoxicity (2.71-, 1.56-, and 1.53-fold, respectively) than the reference compound 5-FU. In addition, OP2 (3.27) exhibited the greatest selectivity index in this group. These compounds can be considered to be model structures for further studies.
Palavras-chave
Sobre autores
K. Kucukoglu
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ataturk University
Autor responsável pela correspondência
Email: kucukogluk35@hotmail.com
Turquia, Erzurum
M. Tugrak
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ataturk University
Email: sakagami@dent.meikai.ac.jp
Turquia, Erzurum
A. Demirtas
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ataturk University
Email: sakagami@dent.meikai.ac.jp
Turquia, Erzurum
H. Sakagami
Division of Pharmacology, School of Dentistry, Meikai University
Autor responsável pela correspondência
Email: sakagami@dent.meikai.ac.jp
Japão, Sakado, Saitama, 350-0283
H. Gul
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ataturk University
Email: sakagami@dent.meikai.ac.jp
Turquia, Erzurum